Agenus

Agenus ROA

The Return on Assets (ROA) of Agenus (AGEN) as of Oct 17, 2026 is 0.05 %. In the previous year, Return on Assets (ROA) was -100.42 % — a change of -100.05% (higher).

ROA

0.05 %

YoY

-100.05%

Last updated:

In 2025, Agenus's return on assets (ROA) was 0.05 %, a -100.05% increase from the -100.42 % ROA in the previous year.

The Agenus ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-117.08 USD
Jan 1, 2019
-69.31 USD
Jan 1, 2020
-84.34 USD
Jan 1, 2021
-5.13 USD
Jan 1, 2022
-53.22 USD
Jan 1, 2023
-78.29 USD
Jan 1, 2024
-100.42 USD
Jan 1, 2025
0.05 USD
The Agenus ROA history
YEARROAYoY
0.05 %-100.05%
-100.42 %+28.26%
-78.29 %+47.12%
-53.22 %+936.36%
-5.13 %-93.91%
-84.34 %+21.69%
-69.31 %-40.80%
-117.08 %+34.26%
-87.20 %+7.80%
-80.90 %+122.97%
-36.28 %-36.36%
-57.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

ROA Details

Understanding Agenus's Return on Assets (ROA)

Agenus's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Agenus's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Agenus's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Agenus’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Agenus stock

Return on Assets (ROA) of Agenus is 0.05 % in 2025.

Return on Assets (ROA) of Agenus changed from -100.42 % to 0.05 %, representing a -100.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Agenus since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Agenus with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Agenus

All Key Metrics — Agenus